- authorisedTherapeutic use (Phase IV)
ACTOR – AUC Control of Tacrolimus in Organ Recipients
This study looks at how the body absorbs a common anti-rejection medicine called Prograf (tacrolimus) after a kidney transplant. Researchers will take blood samples over 12 hours and look at gut bacteria to find safer, more accurate ways to check medicine levels for kidney transplant patients.
Norway - authorisedTherapeutic use (Phase IV)
Influence of Antimicrobial Drugs on Mycophenolic acid and Tacrolimus Pharmacokinetics and the Gut Microbiome in Kidney Transplant Recipients (AXIS)
This study looks at how antibiotics and other infection-fighting medicines affect anti-rejection drugs in kidney transplant patients. Researchers want to see if these medicines change drug levels in the blood or alter the friendly bacteria in the gut, helping doctors prescribe safer doses in the future.
Norway - recruitingTherapeutic confirmatory (Phase III)
A randomized crossover clinical trial regarding the blockage of the mineralocorticoid receptor using Eplerenone on the evolution of arterial stiffness in kidney patients one year after transplant: EVATRAN (The effect of Eplerenone on the evolution of Vasculopathy in renal transplant patients).
This study looks at how a drug called eplerenone affects the stiffness of blood vessels in kidney transplant patients. Researchers want to see if it can improve heart and blood vessel health a year after a kidney transplant.
France - recruitingTherapeutic use (Phase IV)
CALCIGRAN FORTE AND DOSING OF IMMUNOSUPPRESSIVE DRUGS IN KIDNEY TRANSPLANT RECIPIENTS
This study is looking at how a common calcium supplement, Calcigran Forte, affects the levels of medicines taken by people who have had a kidney transplant. We want to make sure these important drugs work as well as they should.
Norway - completedPhase IV
The OPTIMAL trial: do older adults with kidney transplants benefit from lower doses of anti-rejection tablets?
This study looks at how much anti-rejection medicine is best for older people (65+) after a kidney transplant. It compares a higher and lower dose of a common medicine called mycophenolate mofetil (MMF) to see which helps patients live longest and best, with fewest side effects.
United Kingdom - recruitingPHASE2
Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation
This study looks at a new treatment called MIC for people having a living donor kidney transplant. It checks if MIC is safe and helps prevent the body from rejecting the new kidney, potentially with less strong anti-rejection medicines. We are comparing it to standard care.
Germany - recruitingNA
Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT)
This study looks at a blood test for organ transplant patients with Cytomegalovirus (CMV) infection. It aims to see if this test can help doctors decide who really needs antiviral medicine, to avoid unnecessary treatment and its side effects.
France - active not recruitingPHASE2
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
This study looks at a new drug, ALXN2030, to help people who have had a kidney transplant and are now experiencing a problem called antibody-mediated rejection (AMR). We want to see if the drug can help the kidney recover.
United States · Brazil · Canada - active not recruitingNA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
This study looks at whether regular heart checks are really needed for people waiting for a kidney transplant. We want to see if skipping these extra checks after an initial one is just as safe as having them, focusing on preventing serious heart problems.
United States · Canada · Germany - authorisedTherapeutic confirmatory (Phase III)
Randomized controlled trial evaluating the impact of mineralocorticoid receptor blockade by eplerenone on echocardiographic abnormalities among kidney graft recipient under calcineurin inhibitors. KT-CANOPY: Cardiac improvement by eplerenone among patients under cyclosporine or tacrolimus for kidney transplantation.
This study looks at how a drug called eplerenone might improve heart health in people who've had a kidney transplant. We want to see if it can help prevent heart problems and if it changes the size and function of the heart.
France